pharmaphorum
FEBRUARY 9, 2022
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. According to a report by IQVIA last year, there were 3,500 oncology-focused therapeutic candidates in the pipeline, which represents a 75% increase on figures seen in 2015.
Outsourcing Pharma
FEBRUARY 9, 2022
The companyâs analysis of trials conducted around the world last year shows cancers took four of the top five positions, with COVID-19 in second place.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 9, 2022
The digitalisation that we all experience daily has affected the way we engage with stakeholders and patients. But how can we make Customer Engagement effective, and how can we leverage technologies like AI and Marketing Automation to their best potential? The key to success lies in implementing a digital health ecosystem , in order to support the shift from an organization-centric model to a customer-centric model by using digital platforms.
Policy Prescription
FEBRUARY 9, 2022
Mark Cuban’s new online pharmacy venture – the Mark Cuban Cost Plus Drug Company (“Cost Plus Drug”) – will not help overcome the biggest obstacle to drug affordability in America, which is drug company monopolies on patented brand name prescription drugs. When only one company makes a drug and can charge as much as the market will bear, which is the case in the United States, the prices are often outrageous, with several treatments exceeding half a million dollars.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
FEBRUARY 9, 2022
GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. Xevudy (sotrovimab), which was developed with Vir Biotech and has seen its use rise after it was shown to be effective against the Omicron strain of SARS-CoV-2, brought in £958 million, £828 million of that in the last quarter of th
Med Ed 101
FEBRUARY 9, 2022
If you work in geriatrics to any extent at all, you’re likely familiar with anticholinergic activity. If you’ve learned anything, you know that more is NOT better when it comes to anticholinergic adverse effects. We want to avoid these side effects, but how do we apply this mentality from a practical standpoint? Let me share […]. The post Minimizing Anticholinergic Adverse Effects – Case Study appeared first on Med Ed 101.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Times
FEBRUARY 9, 2022
Sustainable lateral flow test kits developed in Birmingham reduce plastic and boost self-testing through ease of use
pharmaphorum
FEBRUARY 9, 2022
Italian online pharmacy group 1000Farmacie has raised €15 million In one of the largest first-round financings in the digital health category. The company – which brings together more than 100 Italian pharmacies using a common, full-service online platform – will use the new funding to expand its network as well as the range of services it offers, according to chief executive Nicolò Petrone. 1000Farmacie was set up with the aim of digitising the Italian pharmacy sector using a vertical marketpla
Pharma Times
FEBRUARY 9, 2022
SMC accepts promising new therapy which offers a better quality of life to patients with epilepsy
pharmaphorum
FEBRUARY 9, 2022
Waiting list numbers for routine hospital treatment in the UK, already at around six million people, will rise and are unlikely to start falling for at least two years, according to Health Secretary Sajid Javid. The comments came following the publication of the UK government’s long-awaited plan for tackling the backlog in elective procedures, which has risen to record levels during COVID-19 as a result of treatment deferrals with around one in nine people in the UK now waiting for care.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
FEBRUARY 9, 2022
AXON today launched a new brand visual identity to showcase its single-minded commitment to being ‘at the forefront of life-changing communications’. In recent months, the company has rolled out a new vision and purpose to ignite change in healthcare through the power of communication. AXON has translated this vision into a striking visual brand identity, with the X representing how we bring together diverse thinking to deliver impactful communications that enable our clients to reach and engage
Expert insights. Personalized for you.
126 
Let's personalize your content